DelveInsight Releases Market Analysis and Drug Insight for EPIDIOLEX

Market research firm DelveInsight has released a comprehensive report providing insights into the market and drug development for EPIDIOLEX. The report forecasts market performance and offers detailed drug insights for EPIDIOLEX, focusing on its use in treating Developmental and Epileptic Encephalopathy (DEE) across the United States, Europe, and Japan.

EPIDIOLEX, known as EPIDYOLEX in Europe, is a prescription, plant-derived cannabis oral formulation developed by GW Pharmaceuticals. It is approved in the US and Europe for treating seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients aged two years and older. The report covers the drug's mechanism of action, dosage and administration, and research and development activities.

The analysis provides an in-depth market assessment, including forecasted sales for EPIDIOLEX in DEE up to 2032. It also includes a SWOT analysis, an overview of market competitors, and details on emerging therapies for these rare epilepsy conditions. DelveInsight's methodology involves data sourced from internal databases, primary and secondary research, and expert analysis.

GW Pharmaceuticals continues to evaluate EPIDIOLEX for other rare epilepsy conditions, with ongoing clinical trials in tuberous sclerosis complex (TSC) and infantile spasms. The US FDA has expanded the approved age range to include children as young as one year. The report notes that NICE has recommended the use of EPIDIOLEX for LGS and Dravet syndrome following evaluations of its clinical and cost-effectiveness.